Insiders · STLN

Kimberly Jo Tzoumakas

Director at Oncology Institute, Inc. (STLN) since February 2026

Kimberly Jo Tzoumakas has filed 7 insider reports with the SEC since January 2022, as director at Oncology Institute, Inc. (STLN) and director at Coherus BioSciences, Inc. (CHRS). The latest filing, on July 29, 2026, reports grant or award at Oncology Institute, Inc. (STLN).

Filings
7
Companies
2
Bought on market
None
Sold on market
None

Companies where Kimberly Jo Tzoumakas is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Oncology Institute, Inc. logo
STLN
Oncology Institute, Inc.
Directorsince February 202646,301$3.20Jul 29, 2026
Coherus BioSciences, Inc. logo
CHRS
Coherus BioSciences, Inc.
Director$0.4099Jun 5, 2024

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Also sits on boards with

Officers and directors who share two or more companies with Kimberly Jo Tzoumakas.

Compare Kimberly Jo Tzoumakas with

Other insiders at the same companies

Questions about Kimberly Jo Tzoumakas

What is Kimberly Jo Tzoumakas's role at Oncology Institute, Inc.?
Kimberly Jo Tzoumakas reports to the SEC as director at Oncology Institute, Inc. (STLN), according to the latest filing on July 29, 2026. Kimberly Jo Tzoumakas has also filed as director at Coherus BioSciences, Inc. (CHRS).
How many shares does Kimberly Jo Tzoumakas own?
After the latest filing that states it, Kimberly Jo Tzoumakas directly owned 46,301 shares of Oncology Institute, Inc. (STLN). Shares held through trusts, funds or family members are reported separately and are not counted here.
Has Kimberly Jo Tzoumakas bought or sold stock recently?
No open-market purchases or sales by Kimberly Jo Tzoumakas are on file. The filings report grant or award.
How do I get alerts when Kimberly Jo Tzoumakas files?
Follow Kimberly Jo Tzoumakas on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by Kimberly Jo Tzoumakas (SEC CIK 0001766666). Totals count each trade once, skipping amendments whose original is on file, from Jan 10, 2022 on. View on SEC EDGAR